Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN trial of brolucizumab versus aflibercept in macular edema secondary to central retinal vein occlusion
NL-OMON55506Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal vein occlusion (CRVO) comparing Brolucizumab with Aflibercept (2 arms). Started Nov 2019; status: active, not recruiting.
02
Drugs
brolucizumabaflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NL-OMON55506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55506.